NASDAQ:IONSIonis Pharmaceuticals Stock Price, Forecast & News

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IONS shares have increased by 24.2% and is now trading at $61.04. View which stocks have been most impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Ionis Pharmaceuticals.

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Ionis Pharmaceuticals.

Ionis Pharmaceuticals Inc (NASDAQ:IONS) released its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.23. The company had revenue of $133 million for the quarter, compared to the consensus estimate of $161.59 million. Ionis Pharmaceuticals had a return on equity of 12.50% and a net margin of 16.79%. The company's quarterly revenue was down 55.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.62 EPS. View Ionis Pharmaceuticals' earnings history.

16 analysts have issued 1 year target prices for Ionis Pharmaceuticals' shares. Their forecasts range from $51.00 to $120.00. On average, they expect Ionis Pharmaceuticals' share price to reach $74.86 in the next year. This suggests a possible upside of 22.6% from the stock's current price. View analysts' price targets for Ionis Pharmaceuticals.

Press coverage about IONS stock has been trending very negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a news impact score of -3.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Ionis Pharmaceuticals.

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), Alibaba Group (BABA), BlackRock (BLK), Gilead Sciences (GILD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Skyworks Solutions (SWKS).

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.04%), Arden Trust Co (0.02%), MERIAN GLOBAL INVESTORS UK Ltd (0.01%), DNB Asset Management AS (0.01%) and IFM Investors Pty Ltd (0.01%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View institutional ownership trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including IFM Investors Pty Ltd, Envestnet Asset Management Inc., and MERIAN GLOBAL INVESTORS UK Ltd. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke. View insider buying and selling activity for Ionis Pharmaceuticals.

IONS stock was bought by a variety of institutional investors in the last quarter, including Arden Trust Co, and DNB Asset Management AS. View insider buying and selling activity for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $61.04.

Ionis Pharmaceuticals has a market capitalization of $8.50 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200 or via email at [email protected]